Table 3.
Characteristics of the included RCTs for genital diseases.
| First author, year | Location of propolis production, chemical composition of propolis | Used form of propolis, amount used | Patient's disease, sample size (randomized/analysed) | Experimental group (intervention, regimen) | Control group (intervention, regimen) | Outcome measures | Main results | AE |
|---|---|---|---|---|---|---|---|---|
| Mousavi, 2016 [29] | Iran, n.r. | Cream, 1 session 3 g | Acute vaginitis, 100/100 | (A) PVC, n = 50, 7 sessions (1 time per day for 7 days) | (B) MVG, n = 50, 7 sessions (1 time per day for 7 days) | (1) Amsel's criteria (2) Gram stain |
(1) Positivea (2) Positivea |
n.r. |
|
| ||||||||
| Vynograd, 2000 [30] | Canada, n.r. | Ointment, n.r. | Herpes viral infection of genitalia and urogenital tract, 90/90 | (A) PO, n = 30, 40 sessions (4 times per day for 10 days) | (B) AO, n = 30, 40 sessions (4 times per day for 10 days) (C) Placebo ointment, n = 30, 40 sessions (4 times per day for 10 days) |
(1) Number of patients who were healed (2) Lesions ① Crusted lesions ② Ulcer lesions ③ Vesicular lesions (3) Infection of herpetic-bacterial (only for 28 infected women) |
(1) Positiveb (2) ① On day 3, Positivec ② (A) better than (B) but NS; (A)a significantly better than (C) ③ Positivea (3) Positiveb |
None |
a P < 0.05; bP < 0.01; cP < 0.001.
AE: adverse events; AO: acyclovir ointment; MVG: metronidazole vaginal gel; n.r.: not reported; PO: propolis ointment; positive: (A) significantly better than (B); PVC: propolis vaginal cream.